secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001193125-22-147984
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology sells Cullinan Pearl to Taiho for $275M; co-develop CLN-081 in U.S.
--------------------------------------------------------------------------------

- Taiho will acquire Cullinan Pearl for $275M upfront, plus up to $130M in regulatory milestones.
- Cullinan and Taiho will co-develop and co-commercialize CLN-081 (EGFR exon20 inhibitor) in the U.S., sharing profits 50/50.
- As of March 31, 2022, cash and investments were $410M; including $275M upfront, pro forma $685M.
- Cash runway extended to 2026 from prior guidance of 2024, excluding potential milestones and U.S. profit share.
- Acquisition expected to close in Q2 2022, subject to HSR and other customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522147984/0001193125-22-147984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522147984/d303365d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-147984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer